Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibition in High-Risk STEMI Patients with MVO
NCT05305911Phase 2Recruiting
- Sponsor
- Minneapolis Heart Institute Foundation
- Start
- Aug 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in ST elevation myocardial infarction (STEMI) and left ventricular dysfunction (2 arms), sponsored by Minneapolis Heart Institute Foundation. Primary endpoints: Change in Left Ventricular End-Systolic Volume Index at 6 months and Change in Left Ventricular End-Diastolic Volume Index at 6 months. Started Aug 2022; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
ST elevation myocardial infarction (STEMI)left ventricular dysfunction
Beyond the preview
Go deeper on NCT05305911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305911.